ArticleGynecology and pelvic medicine2026
Survival trends and prognostic factors of metastatic cervical cancer: a population-based cohort study.
Article in Gynecology and pelvic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic cervical cancer (mCC) remains a highly lethal disease. While clinical trials support the addition of targeted therapy and immunotherapy to chemotherapy, real-world survival trends are less well characterized. This study aimed to evaluate real-world overall survival trends and prognostic factors in mCC patients over the past two decades, in the context of evolving targeted and immunotherapeutic treatments. Methods: We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to evaluate overall survival (OS) trends and prognostic factors among mCC patients diagnosed between 1998 and 2019. Based on major therapeutic milestones, patients were grouped into three calendar cohorts: 1998-2003 (pre-bevacizumab chemotherapy era), 2004-2013 (chemotherapy plus molecular-targeted therapy era), and 2014-2019 (chemotherapy plus immuno-molecular targeted therapy era, after pembrolizumab approval). Kaplan-Meier and Cox regression analyses were used to assess OS and identify independent prognostic variables. Results: Among 1,866 patients with distant mCC [corresponding to International Federation of Gynecology and Obstetrics (FIGO) stage IVB], 53.5% were aged ≥55 years and 67.1% had squamous cell carcinoma (SCC). Median OS increased from 11 months in 1998-2003 to 14 months in 2014-2019 (P=0.04), while the mortality rate declined from 91.6% in 1998-2003 to 75.9% in 2014-2019 (P<0.001). Among patients with SCC, median OS increased from 13 months in 1998-2003 to 16 months in 2014-2019 (P=0.006), whereas no significant survival improvement was observed among those with non-SCC histologies (P=0.48). Multivariable analysis identified SCC histology [hazard ratio (HR) =0.764, 95% confidence interval (CI): 0.670-0.871], lymphadenectomy (HR =0.730, 95% CI: 0.602-0.886), radiotherapy (HR =0.696, 95% CI: 0.619-0.783), and chemotherapy (HR =0.508, 95% CI: 0.452-0.571) were independently associated with improved survival. While age ≥55 years (HR =1.158, 95% CI: 1.045-1.284), Black race (HR =1.339, 95% CI: 1.108-1.620), absence of surgery (HR =2.160, 95% CI: 1.788-2.610), and local surgery alone (HR =1.501, 95% CI: 1.129-1.995) were associated with worse outcomes. Conclusions: Survival for mCC has improved in the past two decades, possibly because of the advances of local therapy and systemic therapy. However, outcomes remain poor for patients with non-SCC histologies, older patients, and Black patients, highlighting the need for individualized, multimodal treatment approaches and better access to emerging therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.